Spirapril

Spirapril

Clinical data
Pregnancy category	D
Routes of administration	Oral
ATC code	C09AA11 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	50%
Metabolism	converted to spiraprilat
Elimination half-life	30 to 35 hours
Excretion	Hepatic and renal
Identifiers
IUPAC name (8S)-7-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl-propyl] amino]propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8- carboxylic acid
CAS Number	83647-97-6
PubChem CID	5311447
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H30N2O5S2
Molar mass	466.616 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ace inhibitor.

Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment. However data on its effect upon the renal function is conflicting.

It is produced synthetically by combining the following two pharmaceutical intermediates:

(S)-1,4-Dithia-7-azaspiro(4,4)-nonane-8-carboxylic acid hydrobromide CAS 75776-79-3

and

N-[1-(S)-ethoxycarbonyl-3-phenylpropyl)-L-Alanine (ECPPA) [2]